In this episode of the Oncology Brothers podcast, we delved into our key takeaways from a session on NTRK Fusion Positive Solid Malignancies, which we had the privilege to moderate during a satellite event at the ASCO 2025 in collaboration with Medscape Global Oncology.
We discussed the prevalence of NTRK fusions, noting that they are common in rare tumors but rare in common ones, such as colorectal and lung cancers. Comprehensive next-generation sequencing (NGS) is crucial for detecting these fusions, as they can be found across various cancer types. We emphasized the importance of both DNA and RNA testing to increase sensitivity and avoid missing opportunities for effective therapies.
Our conversation also covered the available treatment options, including first-generation NTRK inhibitors like larotrectinib and entrectinib, which have shown impressive response rates and improvements in overall survival. We touched on the second-generation agent, repotrectinib, which is used when resistance to first-generation inhibitors occurs.
Additionally, we highlighted the significance of understanding the side effects associated with these treatments, particularly in pediatric patients, where formulation and administration can be challenging. We shared insights from our panelists, including real-world data and case studies that illustrated the effectiveness of NTRK inhibitors in both adult and pediatric populations.
As we wrapped up, we reiterated the importance of comprehensive NGS testing for all cancers to ensure we are identifying these rare NTRK fusion positive solid tumors. We encourage our listeners to stay informed and proactive in their practices.
Thank you for joining us, and be sure to check out the full accredited enduring program by Medscape Global Oncology linked below, and earn your CME credit.
https://www.medscape.org/viewarticle/1002679?src=acdmpart_onc-brothers_1002679